Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) had its price target cut by equities researchers at The Goldman Sachs Group from $25.00 to $21.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the biotechnology company's stock. The Goldman Sachs Group's price target would indicate a potential upside of 166.50% from the stock's previous close.

Several other analysts also recently issued reports on ACRS. HC Wainwright dropped their price target on Aclaris Therapeutics from $50.00 to $43.00 and set a "buy" rating on the stock in a research note on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $38.00 target price on shares of Aclaris Therapeutics in a research report on Tuesday, February 7th. SVB Leerink reaffirmed an "outperform" rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th. BTIG Research lowered their target price on Aclaris Therapeutics from $32.00 to $29.00 and set a "buy" rating on the stock in a research report on Tuesday. Finally, Stifel Nicolaus started coverage on Aclaris Therapeutics in a research report on Tuesday, December 13th. They issued a "buy" rating and a $29.00 target price on the stock. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $32.00.

Aclaris Therapeutics Price Performance

ACRS opened at $7.88 on Tuesday. The business's 50-day moving average price is $14.57 and its two-hundred day moving average price is $15.47. Aclaris Therapeutics has a 1 year low of $5.77 and a 1 year high of $18.96. The company has a market capitalization of $525.52 million, a price-to-earnings ratio of -5.92 and a beta of 0.60.

Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.03. Aclaris Therapeutics had a negative return on equity of 41.71% and a negative net margin of 292.11%. The firm had revenue of $7.80 million for the quarter, compared to the consensus estimate of $1.99 million. During the same quarter last year, the business posted ($0.37) EPS. The company's revenue for the quarter was up 420.0% on a year-over-year basis. Sell-side analysts anticipate that Aclaris Therapeutics will post -1.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Aclaris Therapeutics news, insider Joseph Monahan sold 5,000 shares of the business's stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $79,400.00. Following the transaction, the insider now owns 96,386 shares of the company's stock, valued at $1,530,609.68. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, insider Joseph Monahan sold 5,000 shares of the business's stock in a transaction that occurred on Thursday, December 15th. The stock was sold at an average price of $15.88, for a total transaction of $79,400.00. Following the completion of the sale, the insider now owns 96,386 shares in the company, valued at $1,530,609.68. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider James Loerop sold 4,267 shares of the business's stock in a transaction that occurred on Wednesday, February 8th. The stock was sold at an average price of $13.89, for a total value of $59,268.63. Following the sale, the insider now owns 6,983 shares of the company's stock, valued at approximately $96,993.87. The disclosure for this sale can be found here. Insiders have sold a total of 79,067 shares of company stock valued at $1,074,015 over the last 90 days. 6.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aclaris Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACRS. JPMorgan Chase & Co. lifted its stake in Aclaris Therapeutics by 20.0% during the first quarter. JPMorgan Chase & Co. now owns 44,650 shares of the biotechnology company's stock worth $770,000 after purchasing an additional 7,448 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of Aclaris Therapeutics by 58.5% during the first quarter. MetLife Investment Management LLC now owns 26,282 shares of the biotechnology company's stock worth $453,000 after buying an additional 9,700 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Aclaris Therapeutics by 18.1% during the first quarter. Rhumbline Advisers now owns 55,194 shares of the biotechnology company's stock worth $952,000 after buying an additional 8,469 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Aclaris Therapeutics by 44.2% during the first quarter. Allianz Asset Management GmbH now owns 81,965 shares of the biotechnology company's stock worth $1,413,000 after buying an additional 25,125 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Aclaris Therapeutics by 0.4% during the first quarter. Vanguard Group Inc. now owns 2,728,820 shares of the biotechnology company's stock worth $47,045,000 after buying an additional 10,713 shares in the last quarter. 95.33% of the stock is currently owned by institutional investors.

About Aclaris Therapeutics

(Get Rating)

Aclaris Therapeutics, Inc operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments.

Featured Articles

• Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
• META Platforms May See its Biggest Opening Yet for New Highs
• Penny Stock Vinco Ventures Could Be Big Winner
• Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
• Should You Park Some Capital with Casey's General Stores?
• Crowdstrike Stock: While The Iron Is Hot!

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.